BioXcel Therapeutics (BTAI) Long-Term Debt Repayments (2026)
BioXcel Therapeutics (BTAI) posted quarterly Long-Term Debt Repayments of $2.5 million for Q1 2026.
BioXcel Therapeutics (BTAI) Long-Term Debt Repayments (2026) Analysis & Trends
BioXcel Therapeutics' Long-Term Debt Repayments history runs 1 years deep, the most recent figure standing at $2.5 million for Q1 2026.
- In Q1 2026, Long-Term Debt Repayments changed N/A year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $2.5 million (changed N/A YoY), while the FY2024 annual figure was $2.5 million, changed N/A from the prior year.
- Long-Term Debt Repayments for Q1 2026 stood at $2.5 million.
- The five-year high for Long-Term Debt Repayments was $2.5 million in Q1 2026, with the low at $2.5 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -156,847.56 |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | BioXcel Therapeutics | 24.29 Mn | 24.29 Mn | 160,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.50 Mn |
| Mar 31, 2026 | 2.50 Mn |